Pivotal Therapeutics (PVTTF) 0.1600 $PVTTF
Pivotal Therapeutics announces issuance of U.S. Patent 8,715,648 for its unique 6:1 EPA
HA formulation
PR Newswire - Wed May 07, 10:39AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,715,648 titled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics". This patent covers Pivotal's unique formulation in conjunction with anti-obesity agents for the reduction of body weight in CVD patients and diabetics. This patent has terms that expire no earlier than 2031.
Crossover Healthcare Fund Announces Ownership Interest in Pivotal Therapeutics Inc.
Marketwire - Wed May 07, 5:05AM CDT
Crossover Healthcare Fund ("Crossover"
announces that pursuant to certain acquisitions ("Acquisitions" it has acquired direct or beneficial ownership in securities of Pivotal Therapeutics Inc. (OTCQX: PVTTF)(CSE: PVO) ("Pivotal", consisting of an aggregate of 12,462,768 common shares ("Common Shares", 8,460,521 Common Share purchase warrants ("Warrants" and 1,649.28 debt units convertible into a total of 8,246,400 Common Shares ("Debt Units" in the capital of Pivotal. Prior to the Acquisitions, Crossover beneficially owned or controlled, directly or indirectly, 464,500 Common Shares or 0.6% of the issued and outstanding Common Shares of Pivotal.
Pivotal Therapeutics presented two posters at American Heart Association's ATVB 2014 Scientific Sessions
CNW Group - Tue May 06, 12:50PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it presented two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions held in Toronto, Ontario, Canada, May 1-3, 2014. Both posters discussed Omega-3 deficiency (OM3D) and VASCAZEN(®)'s unique formulation to correct the deficiency.
Pivotal Therapeutics to present at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions
PR Newswire - Thu May 01, 2:47PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it will be presenting two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions in Toronto, Ontario, Canada, May 1-3, 2014.
Pivotal Therapeutics issues correction to 2013 financial results press release
PR Newswire - Thu May 01, 1:40PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announces a correction to its press release issued yesterday entitled "Pivotal Therapeutics Announces 2013 Financial Results".
Pivotal Therapeutics Announces 2013 Financial Results
CNW Group - Wed Apr 30, 8:19PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2013. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics announces resignation of directors
PR Newswire - Wed Apr 23, 4:37PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced the resignations of two of its directors effective April 17, 2014: Dr. John P. Nicholson, Jr. who was appointed on October 30, 2013 following the conclusion of an equity financing, and Mr. James Connolly, who was appointed March 10, 2014 following the closing of the Company's debt financing on March 4, 2014. The two directors announced their intention to resign at a Board teleconference meeting on Thursday April 17, 2014 during discussions on employment agreements with senior management, and written resignations were tendered following the conclusion of the Board meeting. Dr. Nicholson and Mr. Connolly were both nominees of Crossover Healthcare Fund, LLC.
Pivotal Therapeutics grants incentive stock options
PR Newswire - Tue Apr 08, 1:58PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2013. Options to acquire a total of 4,176,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
Pivotal Therapeutics announces issuance of U.S. Patent 8,715,648 for its unique 6:1 EPA
HA formulation PR Newswire - Wed May 07, 10:39AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,715,648 titled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics". This patent covers Pivotal's unique formulation in conjunction with anti-obesity agents for the reduction of body weight in CVD patients and diabetics. This patent has terms that expire no earlier than 2031.
Crossover Healthcare Fund Announces Ownership Interest in Pivotal Therapeutics Inc.
Marketwire - Wed May 07, 5:05AM CDT
Crossover Healthcare Fund ("Crossover"
announces that pursuant to certain acquisitions ("Acquisitions" it has acquired direct or beneficial ownership in securities of Pivotal Therapeutics Inc. (OTCQX: PVTTF)(CSE: PVO) ("Pivotal", consisting of an aggregate of 12,462,768 common shares ("Common Shares", 8,460,521 Common Share purchase warrants ("Warrants" and 1,649.28 debt units convertible into a total of 8,246,400 Common Shares ("Debt Units" in the capital of Pivotal. Prior to the Acquisitions, Crossover beneficially owned or controlled, directly or indirectly, 464,500 Common Shares or 0.6% of the issued and outstanding Common Shares of Pivotal. Pivotal Therapeutics presented two posters at American Heart Association's ATVB 2014 Scientific Sessions
CNW Group - Tue May 06, 12:50PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it presented two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions held in Toronto, Ontario, Canada, May 1-3, 2014. Both posters discussed Omega-3 deficiency (OM3D) and VASCAZEN(®)'s unique formulation to correct the deficiency.
Pivotal Therapeutics to present at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions
PR Newswire - Thu May 01, 2:47PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it will be presenting two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions in Toronto, Ontario, Canada, May 1-3, 2014.
Pivotal Therapeutics issues correction to 2013 financial results press release
PR Newswire - Thu May 01, 1:40PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announces a correction to its press release issued yesterday entitled "Pivotal Therapeutics Announces 2013 Financial Results".
Pivotal Therapeutics Announces 2013 Financial Results
CNW Group - Wed Apr 30, 8:19PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2013. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Therapeutics announces resignation of directors
PR Newswire - Wed Apr 23, 4:37PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced the resignations of two of its directors effective April 17, 2014: Dr. John P. Nicholson, Jr. who was appointed on October 30, 2013 following the conclusion of an equity financing, and Mr. James Connolly, who was appointed March 10, 2014 following the closing of the Company's debt financing on March 4, 2014. The two directors announced their intention to resign at a Board teleconference meeting on Thursday April 17, 2014 during discussions on employment agreements with senior management, and written resignations were tendered following the conclusion of the Board meeting. Dr. Nicholson and Mr. Connolly were both nominees of Crossover Healthcare Fund, LLC.
Pivotal Therapeutics grants incentive stock options
PR Newswire - Tue Apr 08, 1:58PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2013. Options to acquire a total of 4,176,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
